Ventyx Biosciences IncNASDAQ:VTYX
- LAST PRICE4.3158
- TODAY'S CHANGE (%)0.5758 (15.3957%)
- Bid / Lots4.3100/ 1
- Ask / Lots4.3200/ 4
- Open / Previous Close3.7800 / 3.7400
- Day Range
- 52 Week Range
- Volume705,246
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTYX |
|---|---|---|
| 09:32 ET | 17798 | 3.71 |
| 09:34 ET | 6100 | 3.88 |
| 09:36 ET | 7275 | 3.91 |
| 09:38 ET | 10639 | 3.93 |
| 09:39 ET | 8459 | 3.9402 |
| 09:41 ET | 8912 | 3.96 |
| 09:43 ET | 5619 | 3.94 |
| 09:45 ET | 3440 | 3.9591 |
| 09:48 ET | 4615 | 3.94 |
| 09:50 ET | 5515 | 3.9601 |
| 09:52 ET | 3422 | 3.9699 |
| 09:54 ET | 2650 | 3.975 |
| 09:56 ET | 1499 | 3.965 |
| 09:57 ET | 1450 | 3.97 |
| 09:59 ET | 1230 | 3.97 |
| 10:01 ET | 3691 | 3.95 |
| 10:03 ET | 25423 | 3.99 |
| 10:06 ET | 4390 | 3.975 |
| 10:08 ET | 11419 | 4.005 |
| 10:10 ET | 5978 | 4.04 |
| 10:12 ET | 1700 | 4.05 |
| 10:14 ET | 5359 | 4.06 |
| 10:15 ET | 6835 | 4.09 |
| 10:17 ET | 13491 | 4.11 |
| 10:19 ET | 21624 | 4.17 |
| 10:21 ET | 14870 | 4.22 |
| 10:24 ET | 16941 | 4.2514 |
| 10:26 ET | 8822 | 4.23 |
| 10:28 ET | 11568 | 4.2 |
| 10:30 ET | 28343 | 4.1805 |
| 10:32 ET | 9461 | 4.1385 |
| 10:33 ET | 2937 | 4.158 |
| 10:35 ET | 2586 | 4.1515 |
| 10:37 ET | 2274 | 4.17 |
| 10:39 ET | 8574 | 4.22 |
| 10:42 ET | 2457 | 4.232 |
| 10:44 ET | 3223 | 4.26 |
| 10:46 ET | 4653 | 4.225 |
| 10:48 ET | 3878 | 4.22 |
| 10:50 ET | 23600 | 4.2928 |
| 10:51 ET | 10935 | 4.3285 |
| 10:53 ET | 19659 | 4.36 |
| 10:55 ET | 4920 | 4.365 |
| 10:57 ET | 7082 | 4.36 |
| 11:00 ET | 6620 | 4.33 |
| 11:02 ET | 2329 | 4.34 |
| 11:04 ET | 200 | 4.345 |
| 11:06 ET | 3739 | 4.33 |
| 11:08 ET | 9560 | 4.37 |
| 11:09 ET | 9272 | 4.39 |
| 11:11 ET | 5051 | 4.38 |
| 11:13 ET | 1381 | 4.38 |
| 11:15 ET | 2050 | 4.355 |
| 11:18 ET | 8688 | 4.4 |
| 11:20 ET | 5322 | 4.39 |
| 11:22 ET | 5102 | 4.4 |
| 11:24 ET | 5889 | 4.42 |
| 11:26 ET | 19244 | 4.4489 |
| 11:27 ET | 16114 | 4.44 |
| 11:29 ET | 11073 | 4.425 |
| 11:31 ET | 9145 | 4.4 |
| 11:33 ET | 14778 | 4.365 |
| 11:36 ET | 1238 | 4.3631 |
| 11:38 ET | 3698 | 4.37 |
| 11:40 ET | 21864 | 4.305 |
| 11:42 ET | 2307 | 4.325 |
| 11:45 ET | 3958 | 4.24 |
| 11:47 ET | 23681 | 4.2888 |
| 11:49 ET | 875 | 4.275 |
| 11:51 ET | 6453 | 4.31 |
| 11:54 ET | 1455 | 4.31 |
| 11:56 ET | 2475 | 4.3202 |
| 12:00 ET | 2161 | 4.3112 |
| 12:02 ET | 100 | 4.32 |
| 12:03 ET | 300 | 4.3101 |
| 12:05 ET | 1698 | 4.3109 |
| 12:07 ET | 20649 | 4.3388 |
| 12:09 ET | 1056 | 4.35 |
| 12:12 ET | 183 | 4.3488 |
| 12:14 ET | 1528 | 4.3354 |
| 12:18 ET | 5787 | 4.32 |
| 12:20 ET | 930 | 4.31 |
| 12:21 ET | 100 | 4.31 |
| 12:23 ET | 1426 | 4.32 |
| 12:25 ET | 524 | 4.32 |
| 12:27 ET | 967 | 4.31 |
| 12:30 ET | 1150 | 4.305 |
| 12:32 ET | 2187 | 4.305 |
| 12:34 ET | 6004 | 4.33 |
| 12:36 ET | 950 | 4.33 |
| 12:38 ET | 1600 | 4.326 |
| 12:41 ET | 500 | 4.322 |
| 12:43 ET | 5080 | 4.335 |
| 12:45 ET | 6525 | 4.36 |
| 12:48 ET | 567 | 4.35 |
| 12:50 ET | 100 | 4.345 |
| 12:52 ET | 7200 | 4.31 |
| 12:54 ET | 300 | 4.3158 |
Yesterday
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX, from 22 hours ago by Dow Jones
22 hours ago by Dow JonesVTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX, from 23 hours ago by Dow Jones
23 hours ago by Dow JonesVTYX DEADLINE TODAY: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX, from 1:04PM ET on Tuesday Apr 30, 2024 by Dow Jones
1:04PM ET on Tuesday Apr 30, 2024 by Dow JonesClass Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact Levi & Korsinsky, from 12:47PM ET on Tuesday Apr 30, 2024 by Dow Jones
12:47PM ET on Tuesday Apr 30, 2024 by Dow JonesDEADLINE ALERT for VTYX, IRBT, and AVXL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders, from 12:07PM ET on Tuesday Apr 30, 2024 by Dow Jones
12:07PM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ventyx Biosciences Inc | 263.4M | -1.3x | --- |
Invivyd Inc | 264.7M | -1.3x | --- |
Monte Rosa Therapeutics Inc | 266.8M | -2.0x | --- |
RAPT Therapeutics Inc | 268.0M | -2.6x | --- |
Pyxis Oncology Inc | 258.7M | -2.3x | --- |
Opthea Ltd | 269.8M | -1.4x | --- |
Company Information
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Contact Information
- Headquarters
- 12790 El Camino Real, Suite 200SAN DIEGO, CA, United States 92130
- Phone
- 858-945-2393
- Fax
- 302-655-5049
Executives
- Executive Chairperson of the Board
- Sheila Gujrathi
- President, Chief Executive Officer, Founder, Director
- Raju Mohan
- Chief Financial Officer
- Martin Auster
- Chief Scientific Officer
- John Nuss
- Independent Director
- Onaiza Cadoret-manier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $263.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.29 |
Book Value | $4.12 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
